Scorpius Holdings Past Earnings Performance

Past criteria checks 0/6

Scorpius Holdings's earnings have been declining at an average annual rate of -15.9%, while the Biotechs industry saw earnings growing at 10.1% annually. Revenues have been growing at an average rate of 13.5% per year.

Key information

-15.9%

Earnings growth rate

26.9%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate13.5%
Return on equity-144.8%
Net Margin-300.4%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Scorpius Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:1HB0 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2410-30230
31 Mar 2410-32250
31 Dec 237-40260
30 Sep 232-51260
30 Jun 232-50250
31 Mar 231-45230
31 Dec 220-41200
30 Sep 221-38190
30 Jun 221-36180
31 Mar 222-36160
31 Dec 212-35170
30 Sep 212-28140
30 Jun 212-29170
31 Mar 213-27160
31 Dec 203-26150
30 Sep 204-23140
30 Jun 204-2090
31 Mar 203-2190
31 Dec 193-2090
30 Sep 193-2290
30 Jun 195-1990
31 Mar 196-1890
31 Dec 186-1670
30 Sep 184-1460
30 Jun 183-1360
31 Mar 182-1260
31 Dec 172-1260
30 Sep 171-1260
30 Jun 171-1150
31 Mar 170-1150
31 Dec 160-1340
30 Sep 160-164-2
30 Jun 160-195-1
31 Mar 160-214-1
31 Dec 150-2050
30 Sep 150-1742
30 Jun 150-1543
31 Mar 150-1343
31 Dec 140-1243
30 Sep 140-1043
30 Jun 140-1043
31 Mar 140-833
31 Dec 130-923

Quality Earnings: 1HB0 is currently unprofitable.

Growing Profit Margin: 1HB0 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 1HB0 is unprofitable, and losses have increased over the past 5 years at a rate of 15.9% per year.

Accelerating Growth: Unable to compare 1HB0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1HB0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.6%).


Return on Equity

High ROE: 1HB0 has a negative Return on Equity (-144.8%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/09/11 02:04
End of Day Share Price 2024/06/14 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Scorpius Holdings, Inc. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Justin ZelinB. Riley Securities, Inc.
Kristen KluskaCantor Fitzgerald & Co.